期刊
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
卷 139, 期 -, 页码 108-116出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2019.04.020
关键词
Bone; Bone metastases; Endpoint; Skeletal-related event; Symptomatic skeletal event
资金
- Merit Review Award, Medical Research Service, Department of Veterans Affairs [I01 BX000545]
- Bayer
Bone metastases are a frequent complication of solid tumors, leading to significant skeletal sequelae that negatively impact quality of life and survival. Prevention and management of skeletal-related complications are critical treatment goals in oncology. Endpoints used in clinical trials to evaluate skeletal-related complications have evolved. In contrast to single measures of bone health, contemporary clinical trial endpoints reflect composite measures of skeletal-related complications, and increasingly also survival. In addition, key symptomatic components, which are more reflective of quality of life and the patient experience, are being incorporated. Given the evolution and resulting diversity of the endpoints being used in pivotal trials, it is becoming increasingly relevant to clarify the utility and the potential clinical impact of these measures not only within the context of trials but also in the real-world setting. Here, we describe the development and evolution of skeletal endpoints used in trials, and discuss their clinical relevance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据